 COPENHAGEN, Denmark, June 25, 2021 GLOBE NEWSWIRE -- Evaxion Biotech AS Nasdaq: EVAX, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the acceptance of a new scientific paper by the International Conference on Machine Learning ICML 2021 . A draft of the article is available on the open-access scientific server bioRxiv.org . 